TY - JOUR
T1 - Preoperative chemotherapy for lung cancer does not increase surgical morbidity
AU - Siegenthaler, Michael P.
AU - Pisters, Katherine M.
AU - Merriman, Kelly W.
AU - Roth, Jack A.
AU - Swisher, Stephen G.
AU - Walsh, Garrett L.
AU - Vaporciyan, Ara A.
AU - Roy Smythe, W.
AU - Putnam, Joe B.
N1 - Funding Information:
This work was supported in part by the Texas Tobacco Settlement Fund and the Charles and Beverly Adams Fund for Thoracic Surgery Research.
PY - 2001
Y1 - 2001
N2 - Background. Preoperative chemotherapy (C+S) for non-small cell lung cancer (NSCLC) has increased in an attempt to improve survival. Patients receiving C+S potentially may have an increase in postoperative morbidity and mortality compared with surgery alone (S). We reviewed our experience with C+S and S in a tertiary referral center. Methods. Three hundred eighty consecutive patients underwent lobectomy or greater resection for NSCLC between August 1, 1996, and April 30, 1999: 335 patients (259 S; 76 C+S) were analyzed; 45 additional patients were excluded for prior NSCLC, other chemotherapy for other malignancy, or radiation. We compared morbidity and mortality overall, and by subset analysis (clinical stage, pathological stage, procedure, and by protocol use) for both C+S and S patients. Results. Demographics, comorbidities, and spirometry were similar. We noted no significant difference in overall or subset mortality or morbidity including pneumonia, acute respiratory distress syndrome, reintubation, tracheostomy, wound complications, or length of hospitalization. Conclusions. C+S did not significantly affect morbidity or mortality overall, based on clinical stage, postoperative stage, or extent of resection. The potential for enhanced survival in resectable NSCLC justifies continued study of C+S.
AB - Background. Preoperative chemotherapy (C+S) for non-small cell lung cancer (NSCLC) has increased in an attempt to improve survival. Patients receiving C+S potentially may have an increase in postoperative morbidity and mortality compared with surgery alone (S). We reviewed our experience with C+S and S in a tertiary referral center. Methods. Three hundred eighty consecutive patients underwent lobectomy or greater resection for NSCLC between August 1, 1996, and April 30, 1999: 335 patients (259 S; 76 C+S) were analyzed; 45 additional patients were excluded for prior NSCLC, other chemotherapy for other malignancy, or radiation. We compared morbidity and mortality overall, and by subset analysis (clinical stage, pathological stage, procedure, and by protocol use) for both C+S and S patients. Results. Demographics, comorbidities, and spirometry were similar. We noted no significant difference in overall or subset mortality or morbidity including pneumonia, acute respiratory distress syndrome, reintubation, tracheostomy, wound complications, or length of hospitalization. Conclusions. C+S did not significantly affect morbidity or mortality overall, based on clinical stage, postoperative stage, or extent of resection. The potential for enhanced survival in resectable NSCLC justifies continued study of C+S.
UR - http://www.scopus.com/inward/record.url?scp=0035055919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035055919&partnerID=8YFLogxK
U2 - 10.1016/S0003-4975(01)02406-7
DO - 10.1016/S0003-4975(01)02406-7
M3 - Article
C2 - 11308144
AN - SCOPUS:0035055919
SN - 0003-4975
VL - 71
SP - 1105
EP - 1112
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -